COMPARATIVE STUDY ON α1‐ADRENOCEPTOR ANTAGONIST BINDING IN HUMAN PROSTATE AND AORTA

Clinical and Experimental Pharmacology and Physiology

Volumn 21, Issue 5, 1994, Pages 405-411

  Yamada, Shizuo ^a   Suzuki, Mayumi ^a   Tanaka, Chiaki ^a   Mori, Ryutaro ^a   Kimura, Ryohei ^a   Inagaki, Osamu ^b   Honda, Kazuo ^b   Asano, Masaharu ^b   Takenaka, Toichi ^b   Kawabe, Kazuki ^c  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

aorta; prostate; tissue selectivity.; 3H prazosin; 1 antagonists

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; CHLOROETHYLCLONIDINE; NAFTOPIDIL; PRAZOSIN; TAMSULOSIN; URAPIDIL;

AORTA; ARTICLE; DRUG LABELING; DRUG RECEPTOR BINDING; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; PROSTATE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AORTA; BINDING SITES; BINDING, COMPETITIVE; CLONIDINE; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; KINETICS; MALE; MIDDLE AGE; NAPHTHALENES; PIPERAZINES; PRAZOSIN; PROSTATE; SULFONAMIDES;

EID: 0028169438     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1994.tb02534.x     Document Type: Article

References (35)

1. Methods in binding studies
2. A placebo‐controlled double‐blind study of the effect of phenoxy‐benzamine in benign prostatic obstruction
3. 1‐adrenergic receptor
4. 1‐Adrenoceptor subclassification in vascular smooth muscle
5. Phenoxybenzamine reduces bladder outlet obstruction in benign prostatic hyperplasia. A urodynamic investigation
6. Heterogeneity of alphal adrenergic receptors revealed by chloroethylclonidine
7. Effects of prazosin in patient with benign prostatic obstruction
8. Alpha‐adrenoceptors and muscarinic receptors in the isolated human prostate
9. 1‐adrenoceptors
10. 1‐Adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits
11. 1‐adrenoceptors
12. 1‐adrenoceptors which increases cyclic AMP accumulation in rat cerebral cortex
13. 1‐adrenoceptors in hypertrophied prostate
14. 1‐blocker, YM617, in the treatment of benign prostatic hypertrophy
15. 1 adrenergic receptors in human benign prostatic hyperplasia
16. 1‐adrenoceptor binding sites in the brain and prostate
17. The alpha adrenergic properties of terazosin in the human prostatic adenoma and canine brain
18. 1 adrenoceptor subtypes in the human prostate
19. The alpha‐adrenoceptor subtype mediating the tension of human prostatic smooth muscle
20. 1A‐adrenergic receptor
21. Protein measurement with the Folin phenol reagent
22. 1‐adrenergic receptor subtypes distinguished by chloroethylclonidine and WB4101
23. Characterization of the al‐adrenergic control of hepatic CAMP in male rats
24. 1‐adrenoceptor binding sites in rat brain
25. 3H]prazosin binding
26. 1D‐adrenergic receptor cDNA
27. 1‐adrenoceptor subtypes in the regulation of arterial pressure
28. 1 adrenergic receptor subtypes in human prostate
29. 1‐adrenergic receptor subtype
30. The alpha‐adrenergic blocking effect of prazosin on the human prostate
31. 1B‐adrenoceptor antagonist, in the unanesthetized rat: a pharmacological analysis in vivo and in vitro
32. Alpha‐1 adrenoceptors in human prostate: Characterization and alteration in benign prostatic hypertrophy
33. 1 adrenoceptors in human prostates
34. 3H]WB4101: Effect of 6‐hydroxydopamine treatment
35. Clinical evaluation of naftopidil (KT‐611) on urinary obstruction caused by benign prostatic hypertrophydouble blind comparative study compared with prazosin hydrochloride